S&P 500   4,194.92 (+0.36%)
DOW   32,887.59 (-0.06%)
QQQ   347.89 (-0.03%)
AAPL   178.25 (+0.56%)
MSFT   327.57 (-0.25%)
META   269.90 (+1.96%)
GOOGL   123.10 (+0.19%)
AMZN   120.94 (+0.30%)
TSLA   201.79 (-1.05%)
NVDA   386.83 (+2.24%)
NIO   7.28 (-3.32%)
BABA   81.86 (+2.90%)
AMD   117.31 (-0.76%)
T   15.72 (-0.06%)
F   11.96 (-0.33%)
MU   68.42 (+0.32%)
CGC   0.83 (-0.81%)
GE   103.26 (+1.70%)
DIS   88.05 (+0.10%)
AMC   4.57 (+1.56%)
PFE   38.10 (+0.21%)
PYPL   62.64 (+1.05%)
NFLX   399.00 (+0.95%)
S&P 500   4,194.92 (+0.36%)
DOW   32,887.59 (-0.06%)
QQQ   347.89 (-0.03%)
AAPL   178.25 (+0.56%)
MSFT   327.57 (-0.25%)
META   269.90 (+1.96%)
GOOGL   123.10 (+0.19%)
AMZN   120.94 (+0.30%)
TSLA   201.79 (-1.05%)
NVDA   386.83 (+2.24%)
NIO   7.28 (-3.32%)
BABA   81.86 (+2.90%)
AMD   117.31 (-0.76%)
T   15.72 (-0.06%)
F   11.96 (-0.33%)
MU   68.42 (+0.32%)
CGC   0.83 (-0.81%)
GE   103.26 (+1.70%)
DIS   88.05 (+0.10%)
AMC   4.57 (+1.56%)
PFE   38.10 (+0.21%)
PYPL   62.64 (+1.05%)
NFLX   399.00 (+0.95%)
S&P 500   4,194.92 (+0.36%)
DOW   32,887.59 (-0.06%)
QQQ   347.89 (-0.03%)
AAPL   178.25 (+0.56%)
MSFT   327.57 (-0.25%)
META   269.90 (+1.96%)
GOOGL   123.10 (+0.19%)
AMZN   120.94 (+0.30%)
TSLA   201.79 (-1.05%)
NVDA   386.83 (+2.24%)
NIO   7.28 (-3.32%)
BABA   81.86 (+2.90%)
AMD   117.31 (-0.76%)
T   15.72 (-0.06%)
F   11.96 (-0.33%)
MU   68.42 (+0.32%)
CGC   0.83 (-0.81%)
GE   103.26 (+1.70%)
DIS   88.05 (+0.10%)
AMC   4.57 (+1.56%)
PFE   38.10 (+0.21%)
PYPL   62.64 (+1.05%)
NFLX   399.00 (+0.95%)
S&P 500   4,194.92 (+0.36%)
DOW   32,887.59 (-0.06%)
QQQ   347.89 (-0.03%)
AAPL   178.25 (+0.56%)
MSFT   327.57 (-0.25%)
META   269.90 (+1.96%)
GOOGL   123.10 (+0.19%)
AMZN   120.94 (+0.30%)
TSLA   201.79 (-1.05%)
NVDA   386.83 (+2.24%)
NIO   7.28 (-3.32%)
BABA   81.86 (+2.90%)
AMD   117.31 (-0.76%)
T   15.72 (-0.06%)
F   11.96 (-0.33%)
MU   68.42 (+0.32%)
CGC   0.83 (-0.81%)
GE   103.26 (+1.70%)
DIS   88.05 (+0.10%)
AMC   4.57 (+1.56%)
PFE   38.10 (+0.21%)
PYPL   62.64 (+1.05%)
NFLX   399.00 (+0.95%)

Denali Therapeutics (DNLI) Stock Forecast, Price & News

$30.62
+0.40 (+1.32%)
(As of 10:39 AM ET)
Compare
Today's Range
$29.95
$30.62
50-Day Range
$21.91
$32.02
52-Week Range
$20.76
$39.43
Volume
84,014 shs
Average Volume
704,031 shs
Market Capitalization
$4.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.09

Denali Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
72.0% Upside
$52.09 Price Target
Short Interest
Bearish
8.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.90mentions of Denali Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$418,754 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.31) to ($3.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

459th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

66th out of 167 stocks


DNLI stock logo

About Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Stock News Headlines

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Stifel Nicolaus Remains a Hold on Denali Therapeutics (DNLI)
Denali Therapeutics (NASDAQ:DNLI) Trading Down 6.2%
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Why Shares of Denali Therapeutics Are Up Monday
Denali Therapeutics (NASDAQ:DNLI) Price Target Cut to $30.00
Berenberg Bank Remains a Buy on Denali Therapeutics (DNLI)
Wedbush Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)
See More Headlines

DNLI Price History

DNLI Company Calendar

Last Earnings
5/08/2023
Today
6/01/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
380
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$52.09
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+72.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-325,990,000.00
Net Margins
-365.21%
Pretax Margin
-365.19%

Debt

Sales & Book Value

Annual Sales
$108.46 million
Book Value
$7.06 per share

Miscellaneous

Free Float
126,075,000
Market Cap
$4.14 billion
Optionable
Optionable
Beta
1.33

Social Links


Key Executives

  • Ryan J. WattsRyan J. Watts
    President, Chief Executive Officer & Director
  • Alexander O. SchuthAlexander O. Schuth
    Secretary, Chief Operating & Financial Officer
  • Carole HoCarole Ho
    Chief Medical Officer & Head-Development
  • Dana Andersen
    CTO & Chief Manufacturing Officer
  • Joe Lewcock
    Chief Scientific Officer













DNLI Stock - Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings
or view top-rated stocks.

What is Denali Therapeutics' stock price forecast for 2023?

12 brokerages have issued twelve-month target prices for Denali Therapeutics' stock. Their DNLI share price forecasts range from $30.00 to $105.00. On average, they expect the company's stock price to reach $52.09 in the next twelve months. This suggests a possible upside of 72.4% from the stock's current price.
View analysts price targets for DNLI
or view top-rated stocks among Wall Street analysts.

How have DNLI shares performed in 2023?

Denali Therapeutics' stock was trading at $27.81 at the beginning of the year. Since then, DNLI shares have increased by 8.7% and is now trading at $30.22.
View the best growth stocks for 2023 here
.

When is Denali Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our DNLI earnings forecast
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings data on Monday, May, 8th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.70) by $0.10. The firm earned $35.14 million during the quarter, compared to analyst estimates of $29.88 million. Denali Therapeutics had a negative trailing twelve-month return on equity of 40.01% and a negative net margin of 365.21%. The business's quarterly revenue was down 16.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.53) earnings per share.

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?
When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.23%), BlackRock Inc. (6.93%), Temasek Holdings Private Ltd (5.04%), Wellington Management Group LLP (3.80%), State Street Corp (3.35%) and Price T Rowe Associates Inc. MD (2.58%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $30.22.

How much money does Denali Therapeutics make?

Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $4.14 billion and generates $108.46 million in revenue each year. The company earns $-325,990,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis.

How many employees does Denali Therapeutics have?

The company employs 380 workers across the globe.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com.

This page (NASDAQ:DNLI) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -